# A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis

> **NCT06926582** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 305 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** HS-10374 6mg tablets
- **DRUG:** HS-10374-matched placebo tablets

## Key facts

- **NCT ID:** NCT06926582
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-09
- **Primary completion:** 2026-07-09
- **Final completion:** 2026-12-09
- **Target enrollment:** 305 (ESTIMATED)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926582, "A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06926582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*